News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Peplin Release: Underwritten Rights Issue To Raise $10.2 Million
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Peplin Limited (ASX:PEP) announced today an offer to shareholders to raise $10.2 million to fund the first phase II clinical trials for its proprietary skin cancer product PEP005 Topical.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Australia
MORE ON THIS TOPIC
Autoimmune disease
Cullinan Bets $700M+ in Back-Heavy China Deal for Autoimmune T Cell Engager
June 5, 2025
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial
June 4, 2025
·
2 min read
·
Dan Samorodnitsky
Business
Opinion: Investing in Research and Welcoming Global Talent Strengthens America
June 4, 2025
·
4 min read
·
Dr. Chris Otiko
Podcast
M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama
June 4, 2025
·
2 min read
·
Heather McKenzie
